164 related articles for article (PubMed ID: 15867341)
1. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor.
Krüger A; Arlt MJ; Gerg M; Kopitz C; Bernardo MM; Chang M; Mobashery S; Fridman R
Cancer Res; 2005 May; 65(9):3523-6. PubMed ID: 15867341
[TBL] [Abstract][Full Text] [Related]
2. Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model.
Arlt M; Kopitz C; Pennington C; Watson KL; Krell HW; Bode W; Gansbacher B; Khokha R; Edwards DR; Krüger A
Cancer Res; 2002 Oct; 62(19):5543-50. PubMed ID: 12359766
[TBL] [Abstract][Full Text] [Related]
3. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.
Krüger A; Soeltl R; Sopov I; Kopitz C; Arlt M; Magdolen V; Harbeck N; Gänsbacher B; Schmitt M
Cancer Res; 2001 Feb; 61(4):1272-5. PubMed ID: 11245418
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo.
Kapischke M; Fischer T; Tiessen K; Tschesche H; Bruch HP; Kalthoff H; Kruse ML
Int J Oncol; 2008 Jan; 32(1):273-82. PubMed ID: 18097568
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinases-1 in the liver: efficient protection against T-cell lymphoma and colon carcinoma metastasis.
Elezkurtaj S; Kopitz C; Baker AH; Perez-Cantó A; Arlt MJ; Khokha R; Gansbacher B; Anton M; Brand K; Krüger A
J Gene Med; 2004 Nov; 6(11):1228-37. PubMed ID: 15390257
[TBL] [Abstract][Full Text] [Related]
6. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.
Shinoda K; Shibuya M; Hibino S; Ono Y; Matsuda K; Takemura A; Zou D; Kokubo Y; Takechi A; Kudoh S
Int J Oncol; 2003 Feb; 22(2):281-8. PubMed ID: 12527923
[TBL] [Abstract][Full Text] [Related]
7. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: inhibition of matrix metalloproteinases in pancreatic cancer.
Kilian M; Gregor JI; Heukamp I; Hanel M; Ahlgrimm M; Schimke I; Kristiansen G; Ommer A; Walz MK; Jacobi CA; Wenger FA
Prostaglandins Leukot Essent Fatty Acids; 2006 Dec; 75(6):429-34. PubMed ID: 17034997
[TBL] [Abstract][Full Text] [Related]
9. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia.
Klein G; Vellenga E; Fraaije MW; Kamps WA; de Bont ES
Crit Rev Oncol Hematol; 2004 May; 50(2):87-100. PubMed ID: 15157658
[TBL] [Abstract][Full Text] [Related]
10. Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity.
Chen MH; Cui SX; Cheng YN; Sun LR; Li QB; Xu WF; Ward SG; Tang W; Qu XJ
Anticancer Drugs; 2008 Nov; 19(10):957-65. PubMed ID: 18827560
[TBL] [Abstract][Full Text] [Related]
11. Tumor targeting with a selective gelatinase inhibitor.
Koivunen E; Arap W; Valtanen H; Rainisalo A; Medina OP; Heikkilä P; Kantor C; Gahmberg CG; Salo T; Konttinen YT; Sorsa T; Ruoslahti E; Pasqualini R
Nat Biotechnol; 1999 Aug; 17(8):768-74. PubMed ID: 10429241
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of a highly selective gelatinase inhibitor generates active metabolite.
Lee M; Villegas-Estrada A; Celenza G; Boggess B; Toth M; Kreitinger G; Forbes C; Fridman R; Mobashery S; Chang M
Chem Biol Drug Des; 2007 Nov; 70(5):371-82. PubMed ID: 17927722
[TBL] [Abstract][Full Text] [Related]
13. Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells.
Mendis E; Kim MM; Rajapakse N; Kim SK
Bioorg Med Chem Lett; 2006 Jun; 16(12):3105-10. PubMed ID: 16616490
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor.
Bonfil RD; Sabbota A; Nabha S; Bernardo MM; Dong Z; Meng H; Yamamoto H; Chinni SR; Lim IT; Chang M; Filetti LC; Mobashery S; Cher ML; Fridman R
Int J Cancer; 2006 Jun; 118(11):2721-6. PubMed ID: 16381009
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MMP-9 activity following hypoxic ischemia in the developing brain using a highly specific inhibitor.
Ranasinghe HS; Scheepens A; Sirimanne E; Mitchell MD; Williams CE; Fraser M
Dev Neurosci; 2012; 34(5):417-27. PubMed ID: 23171520
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
Williams RN; Parsons SL; Morris TM; Rowlands BJ; Watson SA
Eur J Surg Oncol; 2005 Nov; 31(9):1042-50. PubMed ID: 15993560
[TBL] [Abstract][Full Text] [Related]
17. Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).
Zhang YM; Fan X; Yang SM; Scannevin RH; Burke SL; Rhodes KJ; Jackson PF
Bioorg Med Chem Lett; 2008 Jan; 18(1):405-8. PubMed ID: 17980583
[TBL] [Abstract][Full Text] [Related]
18. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.
Chiappori AA; Eckhardt SG; Bukowski R; Sullivan DM; Ikeda M; Yano Y; Yamada-Sawada T; Kambayashi Y; Tanaka K; Javle MM; Mekhail T; O'bryant CL; Creaven PJ
Clin Cancer Res; 2007 Apr; 13(7):2091-9. PubMed ID: 17404091
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Matrix Metalloproteinase 9 Enhances Rod Survival in the S334ter-line3 Retinitis Pigmentosa Model.
Shin JA; Kim HS; Vargas A; Yu WQ; Eom YS; Craft CM; Lee EJ
PLoS One; 2016; 11(11):e0167102. PubMed ID: 27893855
[TBL] [Abstract][Full Text] [Related]
20. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers.
Turpeenniemi-Hujanen T
Biochimie; 2005; 87(3-4):287-97. PubMed ID: 15781315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
